Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Time trends (2006-2015) of quality indicators in EUSOMA-certified breast centres.

van Dam PA, Tomatis M, Marotti L, Heil J, Mansel RE, Rosselli Del Turco M, van Dam PJ, Casella D, Bassani LG, Danei M, Denk A, Egle D, Emons G, Friedrichs K, Harbeck N, Kiechle M, Kimmig R, Koehler U, Kuemmel S, Maass N, Mayr C, Prové A, Rageth C, Regolo L, Lorenz-Salehi F, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Audisio R, Ponti A; eusomaDB Working Group.

Eur J Cancer. 2017 Nov;85:15-22. doi: 10.1016/j.ejca.2017.07.040. Epub 2017 Sep 4.

PMID:
28881247
2.

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).

Pestalozzi BC, Tausch C, Dedes KJ, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A, Buser K, Borner M, Novak U, Nussbaum CU, Seifert B, Bigler M, Bize V, Vilei SB, Rageth C, Aebi S; Swiss Group for Clinical Cancer Research (SAKK).

BMC Cancer. 2017 Apr 13;17(1):265. doi: 10.1186/s12885-017-3261-1.

3.

Assessment of the extent of microcalcifications to predict the size of a ductal carcinoma in situ: comparison between tomosynthesis and conventional mammography.

Berger N, Schwizer SD, Varga Z, Rageth C, Frauenfelder T, Boss A.

Clin Imaging. 2016 Nov - Dec;40(6):1269-1273. doi: 10.1016/j.clinimag.2016.09.003. Epub 2016 Sep 13.

PMID:
27677056
4.

First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth CJ, O'Flynn EA, Comstock C, Kurtz C, Kubik R, Madjar H, Lepori D, Kampmann G, Mundinger A, Baege A, Decker T, Hosch S, Tausch C, Delaloye JF, Morris E, Varga Z.

Breast Cancer Res Treat. 2016 Sep;159(2):203-13. doi: 10.1007/s10549-016-3935-4. Epub 2016 Aug 13. Review.

5.

Lesions with unclear malignant potential (B3) after minimally invasive breast biopsy: evaluation of vacuum biopsies performed in Switzerland and recommended further management.

Saladin C, Haueisen H, Kampmann G, Oehlschlegel C, Seifert B, Rageth L, Rageth C, Stadlmann S, Kubik-Huch RA; MIBB Group.

Acta Radiol. 2016 Jul;57(7):815-21. doi: 10.1177/0284185115610931. Epub 2015 Nov 8.

6.

The effect of EUSOMA certification on quality of breast cancer care.

van Dam PA, Tomatis M, Marotti L, Heil J, Wilson R, Rosselli Del Turco M, Mayr C, Costa A, Danei M, Denk A, Emons G, Friedrichs K, Harbeck N, Kiechle M, Koheler U, Kuemmel S, Maass N, Marth C, Prové A, Kimmig R, Rageth C, Regolo L, Salehi L, Sarlos D, Singer C, Sohn C, Staelens G, Tinterri C, Ponti A; eusomaDB Working Group:; eusomaDB Working Group.

Eur J Surg Oncol. 2015 Oct;41(10):1423-9. doi: 10.1016/j.ejso.2015.06.006. Epub 2015 Jun 24.

PMID:
26278019
7.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2015 Jan 29;372(5):436-46. doi: 10.1056/NEJMoa1412379. Epub 2014 Dec 11.

8.

Mapping lymph nodes in cancer management - role of (99m)Tc-tilmanocept injection.

Tausch C, Baege A, Rageth C.

Onco Targets Ther. 2014 Jun 24;7:1151-8. doi: 10.2147/OTT.S50394. eCollection 2014. Review.

9.

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group.

N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1.

10.

Papillary lesions of the breast: outcomes of 156 patients managed without excisional biopsy.

Wyss P, Varga Z, Rössle M, Rageth CJ.

Breast J. 2014 Jul-Aug;20(4):394-401. doi: 10.1111/tbj.12283. Epub 2014 May 26.

PMID:
24861903
11.

Treatment of breast cancer in the elderly: a prospective, population-based Swiss study.

Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, Vlastos G, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, Ess S.

J Geriatr Oncol. 2013 Jan;4(1):39-47. doi: 10.1016/j.jgo.2012.08.002. Epub 2012 Aug 24.

PMID:
24071491
12.

MRI-guided vacuum-assisted breast biopsy: comparison with stereotactically guided and ultrasound-guided techniques.

Imschweiler T, Haueisen H, Kampmann G, Rageth L, Seifert B, Rageth C, Freiwald B, Kubik-Huch RA.

Eur Radiol. 2014 Jan;24(1):128-35. doi: 10.1007/s00330-013-2989-5. Epub 2013 Aug 27.

13.

Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients?

Tausch C, Baege A, Dietrich D, Vergin I, Heuer H, Heusler RH, Rageth C.

Eur J Surg Oncol. 2013 Aug;39(8):880-6. doi: 10.1016/j.ejso.2013.05.009. Epub 2013 Jun 2.

PMID:
23735162
14.

Fluctuating mastectomy rates across time and geography.

Garcia-Etienne CA, Tomatis M, Heil J, Danaei M, Rageth CJ, Marotti L, Rosselli Del Turco M, Ponti A.

Ann Surg Oncol. 2013 Jul;20(7):2114-6. doi: 10.1245/s10434-013-2982-x.

PMID:
23640480
15.

German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer.

AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F.

Eur J Cancer. 2013 Jul;49(10):2277-83. doi: 10.1016/j.ejca.2013.01.034. Epub 2013 Mar 13.

PMID:
23490652
16.

The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.

Trojan A, Vergopoulos A, Breitenstein U, Seifert B, Rageth C, Joechle W.

Breast Care (Basel). 2012 Feb;7(1):25-31. Epub 2012 Feb 20.

17.

Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database.

Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, del Turco MR, Ponti A; eusomaDB Working Group.

Eur J Cancer. 2012 Sep;48(13):1947-56. doi: 10.1016/j.ejca.2012.03.008. Epub 2012 Apr 4.

PMID:
22483323
18.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

19.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

20.

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group.

Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Review.

Supplemental Content

Loading ...
Support Center